A sub-study to evaluate safety , tolerability , ease-of-use and patient satisfaction with a single-use autoinjector administering subcutaneous peginterferon-1a ( a pegylated interferon-1a in clinical development ) in a subset of relapsing-remitting multiple sclerosis ( MS ) patients participating in ATTAIN , a long-term dose-frequency blinded extension of the Phase III randomized ADVANCE study .